GlassScriptPhysician profile
Vardhini Desikan
NPI 1295984383
$4,996.66
in general payments reported to CMS, 2019-2025
33 companies · $658 in 2025
The $658 reported for 2025 was more than what a typical Pediatric Endocrinology provider received nationally (typical 2025 total: $294).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $885 · 2020: $314 · 2021: $334 · 2022: $574 · 2023: $1,085 · 2024: $1,146 · 2025: $658.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,869 · Education: $20.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,868.68 |
| Education | $20.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $969.68 | 2019-2025 | Lupron Depot, Synthroid |
| Novo Nordisk INC | $452.36 | 2019-2024 | Norditropin, Sogroya |
| Ascendis Pharma Endocrinology INC | $430.00 | 2022-2025 | Skytrofa |
| Tolmar, INC. | $381.36 | 2023-2025 | Fensolvi |
| Sanofi-Aventis U.S. LLC | $321.25 | 2023-2025 | |
| Insulet Corporation | $319.01 | 2019-2025 | Omnipod |
| Lilly USA, LLC | $233.53 | 2019-2022 | |
| Azurity Pharmaceuticals, INC. | $206.87 | 2023-2024 | Triptodur, Triptodur |
| Arbor Pharmaceuticals, INC. | $170.13 | 2019-2022 | |
| Biomarin Pharmaceutical INC. | $137.92 | 2022-2024 | Voxzogo 1.2mg |
| Endo Pharmaceuticals INC. | $131.75 | 2019-2024 | Supprelin |
| Medtronic, INC. | $119.02 | 2021-2023 | Inpen Smart Insulin Delivery System |
| Ultragenyx Pharmaceutical INC. | $111.83 | 2019-2023 | |
| Sandoz INC. | $99.04 | 2019-2020 | |
| Xeris Pharmaceuticals, INC. | $95.64 | 2021-2024 | Gvoke Hypopen |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endo USA, INC. | $93.81 | 2024 | Supprelin |
| Neurocrine Biosciences, INC. | $88.86 | 2025 | |
| Amneal Pharmaceuticals LLC | $82.97 | 2021-2023 | Unithroid |
| Ipsen Biopharmaceuticals, INC | $64.26 | 2019 | |
| Tandem Diabetes Care, INC. | $62.43 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Takeda Pharmaceuticals U.S.A., INC. | $56.88 | 2024-2025 | Gattex |
| Abbott Laboratories | $46.73 | 2024-2025 | Freestyle Libre |
| Eton Pharmaceuticals, INC. | $43.21 | 2023 | Alkindi |
| Tolmar Pharmaceuticals, INC. | $42.13 | 2021-2022 | |
| Medtronic Minimed, INC. | $41.86 | 2020 | |
| Pfizer INC. | $41.09 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $30.60 | 2024 | Strensiq |
| Beta Bionics, INC. | $26.77 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Ibsa Pharma INC. | $24.45 | 2019 | |
| Rhythm Pharmaceuticals, INC. | $21.45 | 2023 | Imcivree |
| Mannkind Corporation | $19.09 | 2020 | |
| Intuity Medical INC | $17.19 | 2022 | |
| Dexcom, INC. | $13.49 | 2024 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vardhini Desikan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.